Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in five FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$388.49 21.87 (5.97)%

High 393.50 Low 368.30 Volume 2,180,107 Market Cap 40.47B
04/28/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Apr 28

    Regeneron and Sanofi Announce Kevzara® (sarilumab) Biologics License Application Resubmission Accepted for Review by U.S. FDA

    Read on
  • Apr 25

    Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (alirocumab) Injection

    Read on

EVENTS

  • Regeneron Pharmaceuticals Q1 2017 Earnings Conference Call
    May 4, 2017 | 8:30 AM

  • 2017 Annual Meeting of Shareholders
    Jun 9, 2017 | 10:30 AM ET

Events & Presentations

NASDAQ REGN

$388.49 21.87 (5.97)%

High 393.50 Low 368.30 Volume 2,180,107 Market Cap 40.47B
04/28/17 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information